image

Welcome to Remedium Bio Corporate News and Investor Information!

Remedium is a Boston based pre-clinical stage Biotechnology company driven by a single basic principle - we believe that any disease can be cured. In line with this principle, Remedium strives to develop life-changing therapeutics for a broad range of diseases, one treatment at a time - a brilliant today for a better tomorrow.

Remedium Corporate News

  • 2022

    • Remedium Bio to attend 2022 BioFIT conference – 12/22

      BOSTON, Dec 1, 2022 - Remedium Bio is pleased to announce that the company will be attending BioFIT 2022, taking place in Strasbourg, France, on November 29-30th and virtually December 7-8th, 2022. BioFIT is Europe’s leading tech transfer and innovation sourcing event and a premier marketplace for Life Science investments. With over 1000 delegates in attendance from 35 countries, the conference and matchmaking forum are a unique opportunity to highlight Remedium’s lead candidate disease modifying gene therapy for Osteoarthritis and R&D pipeline.

      “We were extremely pleased to have been selected to present at least year’s event and are excited to be back in attendance in 2022" said Frank Luppino, President and CEO of Remedium. "Biofit 2022 is particularly suited to Remedium’s pipeline, with a focus on novel therapeutics as well as a dedicated track focused exclusively on Animal Health innovation". At the 2022 BioFIT, Remedium will highlight its lead candidate disease modifying gene therapy for Osteoarthritis and the Animal Health rheumatology pipeline.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium announces acceptance of abstract for podium presentation at ORS – 11/22

      BOSTON, Nov 15, 2022 - Remedium Bio, a biotechnology company developing a lead candidate disease modifying gene therapy for the treatment of Osteoarthritis (OA) announced today the acceptance of an abstract titled “AAV2-hFGF18 Increases Cartilage Thickness and Promotes Hyaline Cartilage Anabolism” for the Orthopedic Research Society (ORS) Conference. The 2023 ORS meeting will take place February 10th through 14th in Dallas Texas. Remedium’s abstract was selected to be presented at the Podium Spotlight Session on February 13th, highlighting therapeutic delivery to joints. The work presented will review Remedium’s progress in the development of a novel gene therapy for the treatment of OA, which is the only single-injection treatment potentially capable of reversing cartilage loss, based on the clinically proven mechanism of FGF18.

      Dating back to 1954, the Orthopedic Research Society is a global organization focused on musculoskeletal research. Today, the ORS consists of over 4000 members in nearly 50 countries, representing researchers, clinicians, and veterinarians. “We are very excited to have been accepted to present our abstract reviewing the progress made to date in the development of our FGF18 gene therapy treatment for Osteoarthritis at the 2023 ORS” said Frank Luppino, President and CEO of Remedium; “The selection of our abstract for a podium presentation spotlight session is an important milestone highlighting the progress we have made to date”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium appoints Richard Hague to Board of Directors – 11/22

      BOSTON, Nov 8, 2022 – Remedium Bio, Inc., a biotechnology company developing novel gene therapies for large unmet needs, today announced the appointment of Richard Hague to its Board of Directors. Mr. Hague is an accomplished biotechnology executive with extensive multi-discipline experience in rheumatology and with regenerative therapies. "Richard is a highly valued addition to the Remedium team, and his background and expertise across three decades in the industry, with many successes in osteoarthritis and regenerative medicine, will help guide Remedium’s strategy and portfolio development as we embark on the next phase of our growth” said Frank Luppino, CEO of Remedium. "We welcome Richard to our Board and look forward to his contributions.”

      “Since inception, Remedium has rapidly built a strong portfolio of novel gene therapies,” said Mr. Hague. “I am excited to join the Board of Directors at this pivotal stage for the company, and eager to help bring the unique advantages of gene therapy to the treatment of osteoarthritis.”

      Mr. Hague is currently the President and Chief Executive Officer of PolarityTE, a regenerative medicine company developing its lead cell therapy product for the treatment of complex wounds. Before joining PolarityTE, Mr. Hague was the Chief Commercial Officer at Anika Therapeutics, where he led all global commercial activities and had oversight of the R&D and Clinical Research functions. He spent a significant portion of his career at Genzyme and later Sanofi (following Sanofi’s acquisition of Genzyme), where he held positions of increasing responsibility, culminating in his role as VP/General Manager of Sanofi’s Cell Therapy and Regenerative Medicine Business Unit. While at Genzyme, Richard played an integral role in the launch and adoption of the first autologous cell therapy products used in orthopedics and burns. Subsequently, he has led the development and launch of innovative products in multiple markets via the CBER and CDRH regulatory pathways.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium to showcase company at the Canadian Stock Exchange Tech Tuesday – 10/22

      BOSTON, Oct 20, 2022 – Remedium Bio is excited to announce that the company has been invited to showcase its innovative flagship potentially disease modifying gene therapy for Osteoarthritis at the Canadian Stock Exchange (CSE) Tech Tuesday webinar, October 25th. The Tech Tuesdays webinars are sponsored by the CSE and designed to spotlight up-and-coming public and private companies that are shaking up the technology industry. The upcoming event will focus on innovations in orthopedic medicine and highlight Remedium’s progress on its lead candidate for Osteoarthritis.

      “We are very excited to have been invited to present at the CSE’s Tech Tuesday webinar” said Frank Luppino, President and CEO of Remedium Bio. “The event provides an opportunity to showcase our innovative rheumatology portfolio for a new audience interested in cutting edge orthopedic innovation”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium to attend the 2022 Pharma Partnering Summit - 10/22

      BOSTON, Oct 11, 2022 – Remedium Bio will be attending the 2022 Pharma Partnering Summit, taking place live on November 17th and 18th in Boston, Massachusetts. The Pharma Partnering Summit brings together senior executives focused on licensing, collaboration, fundraising, and investment. Remedium will be highlighting its lead candidate disease modifying therapy for Osteoarthritis, dose-adjustable gene therapy platform technology, and neuroprotective treatment for the prevention of neurodegeneration following ischemic stroke at the Summit.

      “We are looking forward to discussing Remedium’s lead candidate and innovative pipeline at the Pharma Partnering Summit” said Frank Luppino, President and CEO of Remedium Bio. “Having advanced our lead candidate disease modifying treatment for Osteoarthritis and pipeline assets through preclinical proof of concept, we are excited about the opportunity to showcase our portfolio to industry leaders, potential partners, and investors”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium invited to present at the Stony Brook 2022 Life Sciences Summit - 10/22

      BOSTON, Oct 5, 2022 – Remedium is excited to announce that the company has been invited to present at the 2022 Life Sciences Summit, organized by the Center for Biotechnology, Stony Brook University. The Life Sciences Summit is an investor and business development conference showcasing professionally managed, private companies at the Pre-Clinical through Phase-IIa stage of development. The two-day program will feature corporate presentations by promising young companies with transformative science that targets clinical unmet needs. The Showcase Sessions will begin on Oct 17, with the event taking place virtually on November 2nd and 3rd.

      “We are honored to have been invited to present at the 2022 Life Sciences Summit for the second year in a row” said Frank Luppino, President and CEO of Remedium Bio. “Having generated in vivo proof of concept data on our lead candidate disease modifying gene therapy for Osteoarthritis, and advanced several pipeline candidates to preclinical efficacy, we look forward to showcasing our progress with industry leaders and investors”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium Bio awarded honorary membership in EPPIC Global - 9/22

      BOSTON, Sep 26, 2022 - Remedium is pleased to announce that the company has been awarded an honorary membership in the the Entrepreneurs & Professionals in Partnership for Innovation in Healthcare Network, and also selected to present at an EPPIC webinar of both the organization’s members as well as industry professionals. This selection was made by EPPICON judges from over 20 applications for the recent pitch competition at the EPPICON 2022 conference in Santa Clara, CA.

      EPPIC is a cross-disciplinary group of healthcare industry leaders, sharing a common vision to bring innovative product to patients and their caregivers through the integration of diverse disciplines and entrepreneurship. Membership in EPPIC brings exclusive benefits including the ability to influence and develop EPPIC's strategic initiatives, as well as access to specialized entrepreneurial content and the broader EPPIC network of investors and industry partners.

      “We are very excited to have had the opportunity to present at the 2022 EPPICON and grateful for the award” said Frank Luppino, President and CEO of Remedium Bio. “As we continue to generate promising data for our lead candidate disease modifying gene therapy for Osteoarthritis, the ability to tap into the EPPIC network is an excellent opportunity to further showcase our technology to industry leaders, potential partners, and investors”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium Bio invited to present at EPPICON 2022 - 9/22

      BOSTON, Sep 14, 2022 - Remedium is pleased to announce that the company has been invited to present at the flagship conference of the Entrepreneurs & Professionals in Partnership for Innovation in Healthcare (EPPICON). EPPICON 2022, taking place on September 17th at the Santa Clara Convention Center, brings together leading professionals, investors, and corporations in a forum to discuss state-of-the-art innovation in healthcare.

      “We are very excited to have been selected and invited to present Remedium at EPPICON 2022” said Frank Luppino, President and CEO of Remedium Bio. “Having further advanced our lead candidate disease modifying treatment for Osteoarthritis, this conference provides a unique opportunity to showcase our technology to industry leaders, potential partners, and investors”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium Bio announces successful $2.3M Expanded Seed raise - 8/22

      BOSTON, Aug 15, 2022 - Remedium Bio, Inc., a biotechnology company developing novel gene therapies, today announced that it has closed more than $2.3M in its expanded seed round financing. Funding from the raise is being used to study Remedium’s lead product, a single-injection gene therapy potentially capable of reversing cartilage loss, in a collaboration with Tufts University School of Medicine scientists researching rheumatic disorders. The financing was led by Sherwood Ventures and included participation from, LongevityTech.Fund, Primo Medical Group, Angel Star Ventures, Apis Health Angels, MicroVentures, and Guindy Alumni Angels.

      Remedium’s lead candidate is the only single injection gene therapy based on the clinically proven anabolic mechanism of FGF18, which has demonstrated the ability to reverse cartilage loss in a placebo controlled, multi-center, randomized clinical trial. Osteoarthritis is the largest unmet need in Rheumatology, presenting a market of $37B with no currently approved therapies capable of slowing or reversing disease progression. Remedium’s novel solution offers the potential to arrest disease progression after a single injection and promote restoration of a more natural, youthful phenotype of articular cartilage.

      “Our technology has the potential to reverse years of age-related cartilage loss, for a disease that currently has no approved therapeutic treatments capable of slowing or reversing progression” said Frank Luppino, President and CEO of Remedium Bio, Inc. “We are extremely excited about the progress made to date, and believe that our gene-augmentation technology can be translated to a number of other age-related pathologies with no currently available disease-modifying options.”

      Remedium was founded by orthopedics industry veterans with proven track records of developing leading therapeutics at companies ranging from start-ups to Fortune 500. Remedium has attracted a number of academic collaborators and medical KOLs to its advisory board including Dr. Timothy McAlindon, MD, MPH, Chief of the Division of Rheumatology at Tufts Medical Center, Professor at Tufts University School of Medicine; Dr. Anastassios Pittas, MD, MS, Chief of the Division of Endocrinology, Diabetes, and Metabolism and Co-Director of the Diabetes and Lipid Center at Tufts Medical Center, Professor at Tufts University School of Medicine; Dr. Jeff Ellsworth, PhD, the pioneer of rhFGF18 technology and CSO of Recardia Therapeutics; Dr. Li Zeng PhD, MA, MS, BA Associate Professor Immunology at Tufts University School of Medicine; and Dr. Kai Zou PhD, Assistant Professor, Department of Exercise and Health Sciences, at the University of Massachusetts, Boston.

      Remedium’s pipeline includes therapeutic indications in Osteoarthritis, Diabetes, Stroke, and other large unmet clinical needs.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium announces abstract acceptance for the ASBMR - 8/22

      BOSTON, Aug 8, 2022 - Remedium Bio, a biotechnology company developing a lead candidate disease modifying treatment for Osteoarthritis (OA), today announced the acceptance of an abstract entitled “Characterization of a Novel FGF18 Gene Therapy for the Treatment of Osteoarthritis” for the 2022 Annual American Society of Bone and Mineral Research (ASBMR) meeting. This year’s ASBMR will take place in Austin Texas on September 9th through 12th as an in-person live event. The work presented will highlight Remedium’s progress in the development of a novel gene therapy for the treatment of OA, which is the only single-injection treatment potentially capable of reversing cartilage loss in OA, based on the clinically proven mechanism of FGF18. The American Society for Bone and Mineral Research is a professional, scientific, and medical society established in 1977 with a current membership of over 4,000 worldwide scientists and clinical researchers representing the fields of orthopedics, rheumatology, and pharmacology.

      “We are honored to have been accepted to present our abstract reviewing the progress made to date in the development of our FGF18 gene therapy treatment for Osteoarthritis at the 2022 ASBMR” said Frank Luppino, President and CEO of Remedium, “We have been additionally invited to present a plenary poster on the first day of the event and are looking forward to sharing our findings at this prestigious forum”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium Bio selected as the RESI Boston Innovator’s Pitch Challenge Finalist - 8/22

      BOSTON, Aug 1, 2022 - Remedium Bio is excited to announce that the company has been selected amongst the finalists to present at the Life Science Nation’s RESI Boston Innovator’s Pitch Challenge event. The Redefining Early Stage Investments (RESI) Boston conference will take place September 21-22 at the Westin Copley Place in person, following more than 2 years in digital format. This 2-day event will include participation from over 450 investors and strategic partners, featuring panel discussions, workshops, and culminating in the Pitch Challenge sessions. Remedium will showcase its lead candidate – only single injection gene therapy potentially capable of reversing cartilage loss in Osteoarthritis, based on a clinically proven mechanism.

      “We are very excited to have been selected amongst the finalists for this year’s first in-person RESI event in Boston” said Frank Luppino, President and CEO of Remedium Bio. “Having made significant progress on our lead candidate treatment for OA and expanded the R&D pipeline, we now look forward to engaging potential partners and investors following the Pitch Challenge sessions”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium’s CEO named among 2022’s Top 10 Most Inspiring CEOs by CLF - 7/22

      BOSTON, Jul 14, 2022 - Remedium Bio is excited to announce that our President and Chief Executive Officer, Frank Luppino was named as one of 2022's Top 10 Most Inspiring CEOs by the C Level Focus (CLF) magazine. C Level Focus is a London-based global media outlet, with a focus on news and information about business, investing, technology (including Biotech and Life Sciences), entrepreneurship, leadership, and affluent lifestyles.

      "I am deeply honored by this recognition and excited to be leading Remedium on its quest to develop therapeutics for a broad range of highly debilitating conditions" said Frank Luppino, President and CEO of Remedium. The article highlights Remedium’s lead candidate gene therapy treatment for Osteoarthritis, a classical disease of aging affecting 1 in 7 adults and comprising a nearly $40 billion dollar market. The article further highlights Remedium's approach to product development using novel, combinatorial modular application of well-characterized technologies, which streamlines the R&D lifecycle, enabling the realization of life-changing medicines more efficiently and effectively.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium’s abstract accepted for the Next Generation Gene Therapy Vectors Summit - 07/22

      BOSTON, Jul 12, 2022 - Remedium Bio, a biotechnology company developing innovative gene therapies, today announced the acceptance of an abstract entitled “Novel High Efficiency Gene Delivery System for Human Primary Preadipocytes and Adipocytes” for the presentation of a poster at the 2nd Annual Next Generation Gene Therapy Vectors Summit in Boston. The work presented will highlight Remedium’s progress in the development of a novel gene delivery technology for use in its Type 2 Diabetes program. This technology is being evaluated in a collaboration at the University of Massachusetts Boston, with Professor Kai Zou’s laboratory, and is intended to support a number of therapeutic indications in Remedium’s pipeline.

      The 2nd Annual Next Generation Gene Therapy Vectors Summit is taking place in Boston on July 18th to 20th, bringing together C-suite leaders, R&D experts, and Business Development professionals from Boston’s leading pharma and biotech companies. “We are excited to present data highlighting the progress on our gene delivery technology”, said Frank Luppino, President and CEO of Remedium; “The Next Generation Gene Therapy Vectors Summit is an important milestone for Remedium, as this technology potentially enables treatments in a number of therapeutic indications.”

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium announces abstract acceptance for the 4th Longevity Therapeutics Summit - 05/22

      BOSTON, May 25, 2022 - Remedium Bio announced today the acceptance of its abstract entitled “Novel FGF-18 Gene Therapy for the Treatment of Osteoarthritis” for presentation of a poster at the 4th Annual Longevity Therapeutics Summit. The poster will present results from preclinical studies of Remedium’s gene therapy for the treatment of Osteoarthritis (OA). FGF18 has been shown to result in structural improvement in OA patients in a Phase 2, placebo controlled, randomized clinical trial. Remedium’s novel gene therapy is a first in class, single-injection, potentially disease-modifying OA treatment, based on the proven chondroregenerative mechanism of FGF-18. Osteoarthritis is the most common form of arthritis and the largest unmet need in rheumatology, affecting an estimated 500 million people worldwide. Currently, there are no approved disease-modifying OA treatments capable of slowing or reversing disease progression.

      The Longevity Therapeutics Summit is taking place in San Francisco on Jun 28th to 30th, bringing together over 100 leading biotech and pharma drug developers, academics, and investors. “We are excited to present data demonstrating proof of concept and the potential unique benefits of our novel gene therapy”, said Frank Luppino, President and CEO of Remedium; “The Longevity Therapeutics Summit is an important milestone for Remedium, and is the first in a series of presentations highlighting the encouraging data being generated on our potentially disease modifying treatment for Osteoarthritis.”

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium partners with the pioneer of FGF18 use for Osteoarthritis - 04/22

      BOSTON, Apr 7, 2022 - Remedium is excited to announce the appointment of Dr. Jeff L. Ellsworth as a scientific advisor for the company’s Rheumatology portfolio. Dr. Ellsworth led the R&D team that originally discovered FGF18’s ability to regenerate cartilage and alleviate infarct-induced injury in an animal model of stroke. He has led several R&D functions at companies including CV Therapeutics, ZymoGenetics, Moderna, and Homology Medicines, and is a renowned authority on Osteoarthritis therapeutics in general and the FGF18 protein specifically. Jeff is also a sought after consultant with a successful track record of providing strategic guidance to emerging biotechnology companies. Jeff holds a PhD in Pharmacology and Cell Biophysics from the University of Cincinnati College of Medicine and a Bachelor of Science in Chemistry from the Indiana University Bloomington. Upon completion of his dissertation defense, Jeff spent a number of years as a post-doctoral fellow at Stanford University School of Medicine researching lipoprotein receptors and lipid metabolism.

      "Jeff is a perfect addition to Remedium’s team of advisors given his pivotal role in the discovery of FGF18’s regenerative potential, and strong track record developing a number of highly impactful regenerative therapies" said Frank Luppino, CEO of Remedium Bio. "Jeff will add significant value to Remedium’s R&D activities, including our lead candidate and pipeline products, and we are extremely excited to partner with him.”

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium accepted into the P4 Precision Medicine Accelerator Program - 03/22

      BOSTON, Mar 3, 2022 - Remedium Bio, Inc. is pleased to announce that the company has been accepted into the P4 Precision Medicine Accelerator Program, a collaboration of UCL, London’s Global University, and Capital Enterprise, the UK’s largest startup ecosystem. Remedium has also been accepted into the sister program, P4SY, focused specifically on collaborations in the South Yorkshire region, the location chosen for one of three Gene Therapy Innovation & Manufacturing Centers to be established in the UK to foster advances in precision medicine.

      “We are excited to participate in these two accelerator programs” said Frank Luppino, CEO of Remedium Bio. “Accessing this world-class entrepreneurship network and burgeoning gene therapy and precision medicine ecosystem will help Remedium increase awareness of our novel gene therapy pipeline, expand access to potential collaborators, and provide access to a network of potential strategic partners.”

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium appoints Dr. Li Zeng as Scientific Advisor Rheumatology - 02/22

      BOSTON, Feb 24, 2022 - Remedium is excited to announce the appointment of Dr. Li Zeng, Associate Professor of Immunology as a scientific advisor for the company’s Rheumatology portfolio. Dr. Zeng currently holds the position of Associate Professor of Immunology at the Graduate School of Biomedical Sciences at Tufts University. She holds a PhD and MA in Cell & Molecular Biophysics from Columbia University with Postdoctoral training at the Harvard Medical School, an MS in Biochemistry from Tsinghua University, and a BA in Plant Physiology & Biochemistry from the Beijing Agricultural University. Currently, Dr. Zeng leads an integrated research laboratory at the Tufts University, Graduate School of Biomedical Sciences focusing on Osteoarthritis research. Her laboratory has generated high-impact publications in journals including Nature Scientific Reports, Nature Laboratory Investigations, Development, Journal of Clinical Investigations, and Osteoarthritis and Cartilage.

      "We are extremely excited to partner with Dr. Li Zeng in this important advisory role, supporting our lead candidate Rheumatology gene therapy" said Frank Luppino, CEO of Remedium Bio. "Dr. Zeng is a world-renowned authority who brings a wealth of scientific and mechanistic knowledge to the company enabling further validation of our potentially disease modifying gene therapy for Osteoarthritis”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium Bio to present at the VC Fast Pitch Event - 01/22

      BOSTON, Jan 18, 2022 - Remedium Bio, Inc. is excited to announce that the company is presenting at the VC Fast Pitch Event taking place virtually on January 20th. This year's forum is hosted by BDVP, a premier business accelerator with a network of 13,000 investors and 40,000 business partners. Remedium will showcase its lead candidate disease modifying Osteoarthritis gene therapy, with a focus on the progress made following the initiation of a broad research partnership in October 2021, and highlight recent developments around Remedium's innovative pipeline of gene therapy products.

      “We are honored to present at the VC Fast Pitch Event allowing us to showcase Remedium and our innovative pipeline” said Frank Luppino, President and CEO of Remedium Bio. “As we begin generating efficacy data on our single-injection gene therapy treatment for Osteoarthritis, we are now approaching several transformative milestones for the organization, which we will highlight at this forum".

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium announces research agreement in Diabetes with UMass Boston - 01/22

      BOSTON, Jan 10, 2022 - Remedium Bio, Inc., a biotechnology company developing novel gene therapies, is pleased to announce it has entered into a Sponsored Research Agreement with the University of Massachusetts Boston to complete pre-clinical efficacy studies on Type 1 and Type 2 Diabetes pipeline candidates. The collaboration will evaluate platform technology for the treatment of Diabetes, with translational potential to the broader Remedium pipeline of single-injection potentially disease-modifying gene therapies. The research is being led by Dr. Kai Zou, PhD, Assistant Professor at the Department of Exercise and Health Sciences under the Robert and Donna Manning College of Nursing and Health Sciences at the University of Massachusetts Boston. Dr. Zou’s laboratory has expertise in characterizing metabolic dysfunction associated with Diabetes and has extensive know-how in the fields of endocrine dysregulation, insulin resistance, impaired glucose metabolism, and associated molecular pathophysiological mechanisms. Dr. Zou has extensive expertise in endocrinology having generated high-impact publications in journals including the Journal of Physiology, Surgery, Physiological Genomics, and International Journal of Obesity.

      “The initiation of this research program is a transformational milestone for Remedium” said Frank Luppino, CEO of Remedium Bio. “Through this partnership, Remedium will expand its development portfolio and validate our gene-therapy dose-adjustment platform, which has broad therapeutic applicability beyond the currently targeted indications”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

  • 2021-2020

    • Remedium Bio to present at the JP Morgan RESI - 12/21

      BOSTON, Dec 20, 2021 - Remedium Bio is excited to announce that the company is presenting at the Redefining Early-Stage Investments (RESI) J.P. Morgan Healthcare conference taking place Jan 11-13 as a virtual online event. As the premier stage for early-stage life science and healthcare companies, venture capital, and partnerships, the JPM RESI will bring together some of the most innovative life-science start-ups with potential pharma and biotech partners as well as leading venture capital companies. Remedium will showcase its innovative pipeline and provide an update on its most recent developments, partnership opportunities, while highlighting its lead candidate potentially disease modifying treatment for Osteoarthritis.

      “We are honored by the invitation to showcase Remedium and our innovative pipeline” said Frank Luppino, President and CEO of Remedium Bio. “Having made significant progress on our lead candidate treatment for OA and expanded the R&D pipeline, we now look forward to engaging potential partners and Series A investors at the JPM RESI”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium Bio appoints Dr. Alexey Seregin as Vice President of R&D - 11/21

      BOSTON, Nov 29, 2021 - Remedium Bio is pleased to announce the appointment of Dr. Alexey Seregin as Vice President of Research and Development. Dr. Seregin is a seasoned leader who brings more than 15 years of experience in the fields of molecular virology and gene therapy to Remedium. He has extensive experience developing viral and non-viral gene therapies in several therapeutic areas including neurodegenerative, neuromuscular, hematologic, metabolic, and gastrointestinal disorders.

      Dr. Seregin brings a strong track record to Remedium Bio, leading a number of high-prolife gene therapy programs at his most recent appointment with Takeda R&D. Previously, Dr. Seregin led Research and Development programs at Biogen, Solid Biosciences, and Bioverativ. Holding a Doctor of Philosophy from The University of Texas Medical Branch at Galveston, Dr. Seregin is the inventor on a number of issued patents covering the development of novel gene therapy technologies and has an extensive list of peer-reviewed publications.

      “We are excited to welcome Dr. Seregin to Remedium Bio” said Frank Luppino, Remedium’s President and CEO. “Alexey is deeply experienced in developing gene therapies and has the technical skillset and scientific depth to enable Remedium’s pipeline of gene therapies targeting diseases with significant unmet needs.”

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium invited to present at BioFIT 2021 - 11/21

      BOSTON, Nov 23, 2021 - Remedium Bio is pleased to announce that the company has been invited to present at the BioFIT 2021, Europe's leading partnering event for early-stage innovation deals and investment rounds in the field of LifeSciences. With over 35 countries represented and more than 1,000 delegates in attendance, BioFIT brings together a broad array of Series A and Seed investors as well as large pharma and biotech companies fostering licensing, collaboration, and equity investment in the LifeSciences sector. This year's event will take place virtually Dec 7th through 9th with the Start-up Slams Therapeutics presentations taking place on Dec 8.

      “We are very excited to have been invited to present at BioFIT" said Frank Luppino, President and CEO of Remedium. "As a highly selective platform, BioFIT presents an excellent venue for a number of hand-picked companies to present their technology to investors and the pharma/biotech corporate community". Remedium will highlight its lead candidate product, a single-injection potentially disease modifying treatment for Osteoarthritis, which is based on a clinically established mechanism of action.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium's COO named Top 10 Most Inspiring COOs by Industry Era magazine - 11/21

      BOSTON, Nov 6, 2021 - Remedium Bio is excited to announce that our Chief Operating Officer (COO), Alex Goraltchouk was named as one of 2021's Top 10 Most Inspiring COOs by the Industry Era magazine. With a focus on the Healthcare and the Life Sciences sector, the Industry Era magazine is the news platform for executives and industry leaders covering topics ranging from technological innovation, to emerging market dynamics and inspiring global trends.

      "I am honored by this recognition and excited to be a part of the Remedium team, developing therapeutics for a broad range of debilitating conditions that account for some of the largest unmet needs in healthcare" said Alex Goraltchouk, COO of Remedium. The article further highlights Remedium's approach to product development using novel, combinatorial modular application of well-characterized technologies, which streamlines the R&D lifecycle, enabling the realization of life-changing medicines more rapidly and efficiently. "We are proud of this nomination as it highlights the quality of the team that Remedium aims to attract and recognizes our efficient approach to value creation" said Frank Luppino, CEO of Remedium Bio.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium recognized by HTGS as one of the most promising deep tech startups - 11/21

      BOSTON, Nov 4, 2021 - We are excited to announce that Remedium has been named one of the Hello Tomorrow Deep Tech Pioneers and invited to present the company at the 2021 Hello Tomorrow Global Summit (HTGS), taking place December 2nd and 3rd in Paris, France. Hello Tomorrow Global Summit is Europe’s largest deep tech event, bringing together over 3,500 investors, corporations, and startups from around the globe. Remedium will showcase its innovative pipeline and lead candidate, the only single-injection gene therapy potentially capable of reversing cartilage loss in Osteoarthritis.

      “The Hello Tomorrow Global Summit is an excellent opportunity to showcase our innovative approach to product development, lead candidate, and product pipeline to a broad audience of global investors” said Frank Luppino, President and CEO of Remedium Bio. Being named amongst the Deep Tech Pioneers by Hello Tomorrow is a recognition bestowed upon a handful of selected startups that are named by HTGS once per year as the most promising startups in Deep Tech. “This selection serves as continued validation of our streamlined approach to modular innovation and its potential for rapid value creation.”

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium selected to present at GIANT Health, global innovation event – 10/21

      BOSTON, Oct 18, 2021 - Remedium Bio is excited to announce that the company has been selected to present its product pipeline and streamlined approach to modular innovation at the GIANT Health Event, Europe’s largest healthcare-technology ecosystem. GIANT is a community of over 200,000 leaders representing global corporations, high-tech startups and health sector investors. This year’s 2-day event will be held on November 30 and December 1 hosting over 450 speakers, 200 exhibitors, and 50,000 participants.

      “We are extremely excited to have been invited to the GIANT Health Conference to showcase the company and our exciting therapeutic pipeline” said Frank Luppino, President and CEO of Remedium. The 2021 GIANTs Pitching for The Future showcase is a premier investment and partnering forum for fast-growing companies focused on developing partnerships with leading investors. “Remedium will highlight our lead candidate single-injection potentially disease modifying treatment for Osteoarthritis, as well as the innovative pipeline and modular approach to product development”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium Bio invited to showcase pipeline at the 2021 Life Sciences Summit - 10/21

      BOSTON, Oct 14, 2021 - Remedium Bio is excited to have been invited to showcase our R&D pipeline at the 2021 LifeSciences Summit – Innovation Pipeline forum. The Life Sciences Summit is a Stony Brook University, Center for Biotechnology Initiative focused on bringing together innovative start-ups and early-stage investors as well as business development representatives from an array of large pharma and biotech companies. This year’s event will be held virtually on November 9th and 10th with featured companies available for discussion via the event partnering system.

      “We are excited to have been selected to showcase Remedium’s lead candidate and innovative pipeline at the Life Sciences Summit” said Frank Luppino, President and CEO of Remedium. The company will present its efficient approach to product development – modular application of proven technologies for the treatment of well characterized pathologies, with a focus on its lead candidate gene therapy, the only single-injection treatment potentially capable of increasing cartilage thickness in Osteoarthritic joints.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium invited to present at Disruptive Innovation Summit – 10/21

      BOSTON, Oct 6, 2021 - Remedium Bio is excited to have been selected to present at the Disruptive Innovation Summit - Health and Biotech, which will take place Live on October 27 at MIT. The summit is an annual innovation conference that enables partnership opportunities, funding, and acquisitions with a focus on Biotech, Life Sciences, and Pharma. With an estimated audience of over 2000 decision makers in attendance, this premier OneTraction Ventures event brings together Fortune 500 companies, Venture Capital, Private Equity, and innovative start-ups for a series of exciting live presentations and networking forums.

      Remedium will showcase its disruptive pipeline, with a focus on the lead candidate, a first-in-class, single injection, potentially disease modifying gene therapy for Osteoarthritis (OA). "Our lead candidate is the only single-injection treatment potentially capable of reversing cartilage loss through the clinically proven anabolic activity of FGF18" said Frank Luppino, President and CEO of Remedium Bio. “We are excited to attend this premier OneTraction Ventures investor event to present Remedium’s innovative approach to product development and exciting R&D pipeline”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium selected to present at the BioFuture Conference - 09/21

      BOSTON, Sep 30, 2021 - Remedium Bio is delighted to announce that the company has been selected to present at the BioFuture 2021 conference in New York City. The BioFuture Conference is a multi-day innovation forum focused on facilitating innovative collaborations, funding, and development partnerships. This year’s event is going to be held October 5th and 6th with additional online forums on October 7th and 8th. "We are excited to be invited to present at Demy Colton’s premier event - BioFuture 2021" said Frank Luppino, CEO of Remedium Bio. Remedium will showcase its lead product candidate – a first-in-class potentially disease modifying treatment for Osteoarthritis as well as ongoing collaborations. Breakout investor events will highlight the strategy for rapid value creation and discuss the broad applicability of its modular product development approach.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium enters collaboration with leading Rheumatology laboratory - 09/21

      BOSTON, Sep 15, 2021 - Remedium Bio, Inc., a biotechnology company developing novel gene therapies, is proud to announce it has entered into a Sponsored Research Agreement with Tufts University’s foremost Rheumatology laboratory to complete pre-clinical efficacy studies on Remedium’s lead gene therapy candidate, a single-injection potentially disease-modifying Osteoarthritis treatment. The research is being led by Dr. Li Zeng, PhD, Associate Professor of Immunology at Tufts University School of Medicine, whose laboratory has developed in vitro, ex vivo, and in vivo testing capabilities for Osteoarthritis (OA). Dr. Zeng is well-known for her extensive expertise in preclinical Rheumatology. Her laboratory has generated high-impact publications in journals including Nature Scientific Reports, Nature Laboratory Investigations, Development, Journal of Clinical Investigations, and Osteoarthritis and Cartilage.

      “The initiation of this research program is a significant milestone for Remedium, and will provide compelling data on our unique approach to the treatment of Osteoarthritis” said Frank Luppino, CEO of Remedium Bio. “Through this partnership, Remedium aims to characterize the functionality of its lead candidate in a range of in vitro, ex vivo, and in vivo efficacy models that will help advance its lead candidate toward IND readiness”.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium invited to present at China Focus 2021 - 08/21

      BOSTON, Aug 11, 2021 - Remedium Bio, Inc. is excited to announce that the company has been invited to present at the 2021 China Focus Online Roadshow (CFOR). The China Focus event is sponsored by the Jiangsu Industrial Technology Research Institute (JITRI), which is a conglomerate of 39 specialty research institutes and a home to over 260 start-ups. With over 10,000 potential business partners, China Focus brings together investors, pharma leaders, and innovators from China and around the world for an exclusive partnering event designed to inspire, educate and foster cross border investment and collaboration in leading biopharma innovations. "We are excited to have been invited to present at CFOR 2021, this is a unique opportunity to present Remedium to a premier panel of investors" said Frank Luppino, President and CEO of Remedium Bio, "Remedium's business model is based on the application of proven technologies in novels ways to treat diseases with well-characterized pathology, creating value for investors rapidly and efficiently - CFOR 2021 is a perfect opportunity to validate this business model with the global investment community."

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium selected to present at the Digital RESI 2021 Pitch Challenge - 08/21

      BOSTON, Aug 2, 2021 - Remedium Bio is excited to announce that the company has been selected to present at the Digital RESI 2021 Innovator's Pitch Challenge. Redefining Early Stage Investments (RESI) conference series is a multi-day investment event that brings together over 450 investors and leading Start-Up Fundraising Executives. This year's digital venue will be held virtually on September 13-15, 2021. RESI, a product of Life Science Nation LLC, is a unique and versatile tool for sourcing deals and advancing innovation across early-stage life science, biotechnology, and healthcare. "We are extremely excited to be selected to present at RESI, this is further validation of the significant market need addressed by Remedium's lead product candidates" said Frank Luppino, CEO of Remedium Bio. Remedium will showcase the lead product candidate and discuss the broad applicability of its modular product development approach.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium appoints Dr Tim McAlindon as Scientific and Medical Advisor - 07/21

      BOSTON, Jul 12, 2021 - Remedium is excited to announce that Dr. Timothy McAlindon, MD, MPH is serving as a scientific and medical advisor for the company’s Rheumatology portfolio. Dr. McAlindon is the Chief of the Division of Rheumatology at the Tufts Medical Center and Professor of Medicine at Tufts University School of Medicine. He is a recognized Key Opinion Leader in Rheumatology, having led the American College of Rheumatology (ACR) Rheumatoid Arthritis (RA) Clinical Treatment Guideline Literature Review Team and chaired the Osteoarthritis Research Society International (OARSI) Treatment Guideline Development Committee. Dr. McAlindon received his Doctorate in of Medicine and Bachelor of Medicine from the University of Southhampton Medical School, his MPH from Boston University School of Public Health, and completed medical training at the Bristol Royal Infirmary, and St. Thomas' Hospital in London, and the Royal United Hospital in the UK. Tim is board certified in Internal Medicine and Rheumatology and is a recipient of a number of prestigious honors and awards including Top Doctor from Boston Magazine and the U.S. News & World Report, 2018 Distinguished Clinical Research Achievement Award from the Clinical Research Forum, as well as the ACR REF Amgen Wyeth Rheumatology Fellowship Training Award. Dr. McAlindon is an author of numerous scientific publications in a broad range of high-impact factor journals including the Journal of the American Medical Association (JAMA) and Annals of Internal Medicine with a research focus in Rheumatoid and Osteoarthritis. "We are extremely excited to partner with Dr. Tim McAlindon in this important advisory role, supporting our lead candidate Rheumatology gene therapy" said Frank Luppino, CEO of Remedium Bio. "Tim is a world-renowned authority who brings a wealth of scientific, regulatory, and clinical experience that enables further validation of our exciting pipeline".

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium selected to present at the Unicorn Cup Finals - 07/21

      BOSTON, Jul 8, 2021 - Remedium is excited to announce that the company has been selected to present at the Unicorn Cup Finals on July 15, 2021. The Unicorn Cup is the world's largest start-up pitch contest attended by over 1000 premier Venture Capital firms and Angel Investors. From a long list of applicants, 7 companies were selected to present at the North America cup on July 8, 2021, and only 2 companies were selected to advance to the Unicorn Cup Finals representing North America. According to the Startup Network, the organizer of the event, winners of the Unicorn Cup have raised over $296 million in funding. "This is an incredible opportunity to further validate Remedium's business model and our ability to provide significant value to our investors" said Frank Luppino, President and CEO of Remedium. "We are extremely excited to have been selected to present Remedium at the North America Cup, and now to be one of only two companies selected to represent North America at the Unicorn Cup Finals".

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium appoints Dr Anastassios Pittas as Scientific and Medical Advisor - 06/21

      BOSTON, Jun 30, 2021 - Remedium Bio, Inc. is extremely excited to announce that Dr. Anastassios Pittas will serve as a Scientific and Medical Advisor on the company’s Endocrinology portfolio. Dr. Pittas is the Chief of the Division of Endocrinology, Diabetes, and Metabolism and Professor of Medicine at Tufts University. He is a recipient of a number of prestigious honors and awards including multiple consecutive Top Doctor awards from Boston Magazine, Biomedical Research Exemplar Award which honors individuals doing high-quality, high-impact, federally-funded research who also maintain an impressive reputation for professionalism and integrity in their work as well as the Donna Seto-Young Award, which recognizes meritorious achievement in the advancement of science, education, practice of medicine or improvement of human health and well-being. Dr. Pittas holds a Bachelor of Science in Biology from MIT, a Master of Science in Clinical Research from the Sackler School of Biomedical Sciences at Tufts University, an MD from the Weill Medical College of Cornell University, completed his Internal Medicine Residences at the New York Presbyterian Hospital, and a Fellowship in Endocrinology, Diabetes, and Metabolism at the Tufts Medical Center. "Partnering with Dr. Pittas brings significant subject matter expertise in Endocrinology and helps Remedium validate its multiple Diabetes pipeline candidates from a clinical perspective" said Frank Luppino, CEO of Remedium Bio. "We are extremely excited to be working with Dr. Pittas and are looking forward to evaluating our novel and proprietary approaches to treating Type 1 and Type 2 diabetes with gene therapy".

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium Bio appoints Alex Goraltchouk as Chief Operating Officer - 06/21

      BOSTON, Jun 11, 2021 - Remedium Bio, Inc. is excited to announce the appointment of Alex Goraltchouk as the Chief Operating Officer. Alex brings 16 years industry experience developing and industrializing biologics and gene therapies at companies including Allergan, Biogen, and Regeneron. Alex’s experience, which ranges from start-up to Fortune 500 spans the development, industrialization, and launch of a number of market-dominant brands including Spinraza (SMA antisense oligonucleotide), Benepali (TNF inhibitor), Kevzara (IL-6 inhibiting monoclonal antibody), and Praluent (PCSK9 inhibiting monoclonal antibody). With a focus on endocrinology, rheumatology, and cardiovascular diseases, Alex’s functional expertise allow the company to further strengthen the R&D, Operations, Quality, and Project Management organizations. Holding a Bachelor in Materials Engineering and a Master in Chemical Engineering from the University of Toronto, an MBA and Master of Science in Finance from Indiana University, and a Master of Microbiology and Cell Sciences from the University of Florida, Alex possesses a broad scientific background in several disciplines that add significant value to Remedium’s development efforts. Alex is a Cornell certified Six Sigma Black Belt, holds an MIT MicroMasters in Supply Chain Management, a Bioinformatics MicroMasters from the University of Maryland University College, a Stanford Certificate in Genetics and Genomics, and is a Certified Project Management Professional enabling the company’s scientific advancement and operational efficiency. “I am delighted to welcome Alex to Remedium” said Frank Luppino, Remedium’s President and CEO. “Alex has broad technical capabilities and demonstrated leadership experience that align perfectly with Remedium’s mission to develop novel gene therapies for diseases with significant unmet needs.”

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium Bio, Inc. secures Seed Round of financing - 04/21

      BOSTON, Apr 16, 2021 - Remedium Bio, Inc. a Boston based biotechnology company focused on developing curative therapies in a broad range of diseases, announced today the funding of the Seed Series Financing round, raising over $1.2 million to build out the management team and advance the lead candidate molecules through pre-clinical efficacy.

      With this financing, Remedium shareholders will benefit from significant value creation via the advancement of multiple molecules through discovery and pre-clinical development within the company's core platforms including gene delivery, growth factor expression, and disease reversal. Proceeds from Remedium's financing will be used to initiate operations, secure key leadership personnel, complete in vitro and in vivo efficacy studies for our lead program, and initiate in vitro efficacy for the second pipeline candidate. Further to the addition of top talent to Remedium's team, the company will use the funds to secure key strategic partnerships with academic institutions and suppliers, hire a world-renowned scientific advisory board, and support a number of IND-enabling studies.

      "We are highly excited about securing this financing for Remedium, a foundational investment which will enable the company to build the infrastructure and create the data to validate the pre-clinical biology of our lead candidates," said Frank Luppino, President and CEO of Remedium Bio, Inc.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium to present at the 2020 Octane OC LaunchPad Investment Forum - 10/20

      BOSTON, Sep 3, 2020 - Remedium Bio, Inc. is excited to be selected as the LaunchPad Finalist at the Octane OC MedTech Innovation Forum, 2020. "We are delighted to have been invited to present in the Octane OC MedTech Innovation Forum 2020 as part of the finalist companies! This is indeed a high vote of confidence for our technology and business model." - said Frank Luppino, President and CEO of Remedium Bio. "Our mission to cure dibilitating diseases by combining proven therapeutic modalities in a novel, innovative approach presents a unique opportunity for our shareholders and potential investors; we are excited to share our progress to date at the Octane OC 2020 forum!". Remedium Bio, a Boston based gene therapy start-up, is focused on developing curative therapies in a broad range of diseases is advancing it's lead candidate toward IND-readiness in 2022.

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

    • Remedium Bio appoints Frank Luppino as President and CEO - 01/20

      BOSTON, Jan 9, 2020 - Remedium Bio, Inc. is delighted to announce the appointment of Frank Luppino as President and Chief Executive Officer, Treasurer and Chairman of the Board starting Jan 10, 2020. Mr. Luppino brings over 25 years product development, industrialization, and commercial launch experience at public and private companies including Anika Therapeutics, Bionostics, and Black & Veatch. Serving as the Chief Operating Officer at Anika Therapeutics, Frank has extensive demonstrated experience leading R&D, Operations, Regulatory, Clinical, and Supply Chain organizations. Further to his broad cross-functional expertise, Frank was instrumental at leading the launch of a series of blockbuster biologic, cell therapy, and drug-device combination products including CingalTM, MonoviscTM, HyalofastTM, and TactosetTM. Finally, Frank’s experience spans a broad range of therapeutic areas including rheumatology, soft tissue regeneration, and ophthalmology, bringing significant business, technical, clinical, and regulatory expertise to the company.

      “Remedium is at an exciting, foundational stage of its corporate evolution, with a highly innovative pipeline of disruptive, curative therapies, Remedium is well positioned to successfully advance these high-value product candidates to the clinic and beyond, creating value for our shareholders,” said Mr. Luppino. “I look forward to building the Remedium team and advancing our lead candidates through pre-clinical development and driving business value creation.” 

      Contact Remedium: info@remedium-bio.com
      Source: Remedium Bio, Inc.

investor faq

  • what we do
    Remedium bio at a glance

    Remedium Bio, Inc. is a biotechnology company focused on the development of curative therapies for a broad range of pathologies. Our people passionately believe that any disease can be cured and are tirelessly working to deliver therapies to patients for a broad range of therapeutic categories. Grounded in our premise, Remedium scientists discover and develop therapies by appropriately matching treatment modalities with specific disease pathophysiology to replace or augment missing, degenerated, or damaged tissues one treatment at a time.

    Our team is located in the Boston area, a modern-day Mecca of Biotechnology. We are founded on the vision of changing lives via curative breakthroughs with a firm scientific foundation with the goal of creating a company that changes the way we think about treating disease.

  • Our people
    Our people - the Remedium team

    Our people are at the core of everything we do, they are what makes Remedium special, what makes our innovations unique, the driving force behind our vision that any disease can be cured. With this in mind, Remedium strives to hire the most talented professionals in the industry, the brightest minds with the most open hearts - adventurers with an inner child, glass half full, looking at the world through rose colored glasses.

    As a company we firmly believe in diligently and persistently investing in our people, supporting training, education, and growth, every step of their way. Inclusion and diversity are at our core, acceptance of all cultures and ideas is the Remedium gold standard, and it is upon this edifice that we venture to build a company to cure one disease at a time - a brilliant today for a better tomorrow.

  • Our science
    The ideas that drive our therapies

    Science is at the foundation of everything we do at Remedium - a uniting principle that innovation, data-driven analysis, and a culture conducive to open discussion that promotes a healthy debate is essential to ideation and delivery of the ideas as treatments to patients. At the core of our values are the principles that all decisions should be supported by data, all scientific ideas are worthy of careful consideration, and turning ideas into medicine is the most noble pursuit of humanity.

  • Ethical commitment
    A high ethical and social bar

    At Remedium, we are firmly committed to upholding the highest ethical standards including integrity, honesty and truthfulness, multicultural and intellectual diversity, respect for all ideas and individuality, inclusion, transparency, freedom of expression, and respect for the dignity and rights of all individuals. Furthermore, we strive to achieve the highest standards in Corporate Social Responsibility and create a sustainable future for our People, Community, and Environment.

    Remedium and our highly-valued team strives to exercise this commitment in everything we do. As members of the Biotechnology community we feel a heightened need to hold ourselves to the highest standards of ethical responsibility in addition to fully abiding by international, federal, and state laws and regulations, following internal policies and industry best practices wherever and whenever possible.

Remedium's current investors

Background Image

remedium bio

Learn more about why we believe that any disease can be cured.

about us

Get In Touch

We are always interested in starting a new conversation and are looking forward to hearing from you. Thank you in advance for your inquiry and please have a wonderful day!


1116 Great Plain Ave, Suite 203
Needham, MA
02492


E: info@remedium-bio.com
P: +1 (978) 467 5217